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Dysregulation of Antioxidant Mechanisms
Contributes to Increased Oxidative Stress
in Calcific Aortic Valvular Stenosis in Humans
Jordan D. Miller, PHD,* Yi Chu, PHD,*§ Robert M. Brooks, BS,* Wayne E. Richenbacher, MD,‡
Ricardo Peña-Silva, MD,*† Donald D. Heistad, MD*†§
Iowa City, Iowa
Objectives The aim of this study was to determine whether oxidative stress is increased in calcified, stenotic aortic valves
and to examine mechanisms that might contribute to increased oxidative stress.
Background Oxidative stress is increased in atherosclerotic lesions and might play an important role in plaque progression
and calcification. The role of oxidative stress in valve disease is not clear.
Methods Superoxide (dihydroethidium fluorescence and lucigenin-enhanced chemiluminescence), hydrogen peroxide
(H2O2) (dichlorofluorescein fluorescence), and expression and activity of pro- and anti-oxidant enzymes were
measured in normal valves from hearts not suitable for transplantation and stenotic aortic valves that were re-
moved during surgical replacement of the valve.
Results In normal valves, superoxide levels were relatively low and distributed homogeneously throughout the valve. In ste-
notic valves, superoxide levels were increased 2-fold near the calcified regions of the valve (p 0.05); noncalcified
regions did not differ significantly from normal valves. Hydrogen peroxide levels were also markedly elevated in calci-
fied regions of stenotic valves. Nicotinamide adenine dinucleotide phosphate oxidase activity was not increased in
calcified regions of stenotic valves. Superoxide levels in stenotic valves were significantly reduced by inhibition of ni-
tric oxide synthases (NOS), which suggests uncoupling of the enzyme. Antioxidant mechanisms were reduced in calci-
fied regions of the aortic valve, because total superoxide dismutase (SOD) activity and expression of all 3 SOD iso-
forms was significantly decreased. Catalase expression also was reduced in pericalcific regions.
Conclusions This study provides the first evidence that oxidative stress is increased in calcified regions of stenotic aortic
valves from humans. Increased oxidative stress is due at least in part to reduction in expression and activity of
antioxidant enzymes and perhaps to uncoupled NOS activity. Thus, mechanisms of oxidative stress differ greatly
between stenotic aortic valves and atherosclerotic arteries. (J Am Coll Cardiol 2008;52:843–50) © 2008 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.043d
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aeplacement of the aortic valve in patients with symptom-
tic, calcific aortic valve stenosis is the most common
alvular surgical procedure performed in the U.S. (1). Risk
actors associated with the development of aortic valve
tenosis are similar to those of atherosclerosis and include
lder age (2,3), male gender, hypertension, smoking, hyper-
holesterolemia (3), and diabetes (1,3).
Calcified lesions in stenotic aortic valves resemble ath-
rosclerotic lesions and contain calcium (4), oxidized low-
rom the Departments of *Internal Medicine, †Pharmacology, and ‡Cardiothoracic
urgery, University of Iowa Carver College of Medicine, Iowa City, Iowa; and the
Veterans Affairs Medical Center; Iowa City, Iowa. Studies were supported by
ational Institutes of Health grants HL-086160, HL-62984, and NS-24621; funds
rovided by the Veterans Affairs Medical Service; and a Carver Research Program of
xcellence.m
Manuscript received November 12, 2007; revised manuscript received May 1, 2008,
ccepted May 27, 2008.ensity lipoproteins, areas of neovascularization (5,6), high
evels of matrix-remodeling enzymes (7–9), and apoptotic
ells within the valvular plaque (10–12). A population of
ells in calcified aortic valves is indistinguishable from
steoblast and osteoclast cells (13,14), which strongly sug-
ests that the deposition of calcium and progression of
ortic valve stenosis is an active process. Signaling cascades
elated to osteoblast differentiation have been examined in
alcified aortic valves (5), but upstream activators of these
athways have been elusive.
See page 851
Increases in oxidative stress might play a critical role in
he initiation and progression of atherosclerotic plaques
s well as differentiation of cultured vascular smooth
uscle cells into a more osteoblast-like phenotype (15).
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844 Miller et al. JACC Vol. 52, No. 10, 2008
Oxidative Stress in Aortic Valve Stenosis September 2, 2008:843–50In atherosclerotic plaques, in-
creased oxidative stress seems
to be due primarily to increases
in nicotinamide adenine dinu-
cleotide phosphate (NADPH)
oxidase activity, with no change
or an increase in activity of
antioxidant enzyme activities
(16).
We obtained preliminary ev-
idence for increased oxidative
stress in an experimental mouse
model of aortic valve stenosis
(17). It is not known whether
oxidative stress is increased in
alcified aortic valves in humans or whether mechanisms
hat increase or protect against oxidative stress are al-
ered. The purpose of this study was to test the hypoth-
sis that oxidative stress is increased in stenotic aortic
alves in humans and to examine mechanisms that
ontribute to increases in oxidative stress in calcific aortic
alve disease.
ethods
ubject characteristics and methods for tissue acquisition,
istological analysis (Von Kossa, Alizarin Red), detection of
eactive oxygen species (dihydroethidium and dichlorofluo-
escein fluorescence, lucigenin chemiluminescence), mea-
urements of gene expression (quantitative real-time
everse-transcriptase polymerase chain reaction), spatial dis-
ribution of proteins (fluorescent immunohistochemistry),
nd enzyme activity (NADPH oxidase and superoxide dis-
utase [SOD] activity) are detailed in the Online Appendix.
tatistics. Group data are expressed as mean  SEM.
omparisons between groups were made with unpaired t
ests assuming unequal variances (Welch t test). Bonferroni
orrections were used to control for multiple comparisons.
ignificance was defined as   0.05.
esults
xidative stress in aortic valves. SUPEROXIDE. In nonste-
otic human aortic valve tissue, dihydroethidine (DHE)
uorescence was relatively low and evenly distributed
hroughout the valve (Fig. 1A). In contrast, valves from
atients with aortic stenosis had intense oxyethidium fluo-
escence near the calcified regions of the valve that progres-
ively declined as the distance from the calcified regions
ncreased (Figs. 1B to 1D) and was markedly reduced by
olyethylene glycol SOD (PEG-SOD) (data not shown).
ucigenin-enhanced chemiluminescence confirmed that su-
eroxide levels were much higher in calcified regions of the
tenotic valve than in both normal and noncalcified valve
egions (Fig. 1E) (p  0.05); superoxide levels were similar
n noncalcified regions of the stenotic valves and in normal
Abbreviations
and Acronyms
DHE  dihydroethidine
L-NAME  nitro-L-arginine
methyl ester
mRNA  messenger
ribonucleic acid
NADPH  nicotinamide
adenine dinucleotide
phosphate
NOS  nitric oxide
synthase
SOD  superoxide
dismutaseissue (Fig. 1E) (p  NS). d2O2. In nonstenotic human aortic valve tissue, H2O2 levels
ere very low and evenly distributed throughout the valve,
s estimated by the PEG-catalase inhibitable fluorescence of
ichlorofluorescein (Figs. 2A and 2B). In calcified valves,
owever, H2O2 levels were significantly increased in the
alcified and peri-calcific regions of the valve versus regions
urther away from the calcified mass (Figs. 2C to 2E).
ntioxidant enzymes. SOD. Expression (messenger ribo-
ucleic acid [mRNA] levels) of copper-zinc superoxide
Figure 1 Superoxide Levels Detected With DHE Fluorescence
and Lucigenin-Enhanced Chemiluminescence
Superoxide (red fluorescence) in a normal (A) and stenotic (B) aortic valve
detected with dihydroethidine (DHE) fluorescence. Superoxide levels were mark-
edly elevated near the calcified (calc) region of the valve and were markedly
reduced by the addition of polyethylene glycol superoxide dismutase. Magnified
images of noncalcified (non-calc) and calcified regions of a stenotic valve with
DHE staining are shown in C and D. (E) Superoxide levels measured with
lucigenin-enhanced chemiluminescence in corresponding regions of normal and
stenotic valves (n  14 control valves, n  20 stenotic valves; *p  0.05 vs.
noncalcified stenotic tissue; #p  0.05 vs. base and tip of normal valves).imutase (SOD1), manganese SOD (SOD2), or extracel-
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September 2, 2008:843–50 Oxidative Stress in Aortic Valve Stenosisular SOD (SOD3) did not differ significantly between
ormal tissue and noncalcified regions of stenotic valves.
owever, in calcified regions of the stenotic valves, mRNA
Figure 2 H2O2 Detected With DCF Fluorescence
Hydrogen peroxide (H2O2) in a normal (A) and stenotic (C) aortic valve
detected with dichlorofluorescein (DCF) fluorescence. Levels of H2O2 were
markedly elevated near the calcified regions of the valve, and most of the DCF
fluorescence was eliminated by pre-incubation of the slide with polyethylene
glycol (PEG)-catalase (CAT) (B and D). (E) The PEG-CAT–inhibitable fraction of
DCF fluorescence in normal (base and tip regions) and stenotic (calcified and
noncalcified regions) aortic valves (n  4 normal valves, n  7 stenotic valves;
*p  0.05 vs. noncalcified stenotic tissue, #p  0.05 vs. base region of nor-
mal valves). Abbreviations as in Figure 1.
Figure 3 SOD Expression and Activity in Normal and Stenotic A
(A) Expression of the 3 superoxide dismutase (SOD) isoforms in normal and nonc
stenotic valves). (B) Regional total SOD activity in stenotic aortic valves (n  10 n
noncalcified stenotic tissue). mRNA  messenger ribonucleic acid; other abbreviatevels for CuZnSOD, MnSOD, and ecSOD were signifi-
antly reduced compared with normal tissue and were
ecreased by 75  8%, 66  13%, and 81  8%,
espectively, when compared with noncalcified regions of
he same valve (Fig. 3A). Total SOD activity was also
ignificantly reduced by 47  12% (Fig. 3B).
ATALASE. Catalase mRNA levels were reduced by 63 
% in noncalcified stenotic tissue compared with normal
issue (p  0.05). Further reductions in catalase expression
ere observed in the calcified regions of stenotic valves,
here mRNA levels for catalase were reduced by 89  3%
ompared with normal valves (p  0.05) (Fig. 4A).
ources of reactive oxygen species. In all aortic valves,
ox1 mRNA expression was below detectable limits. Ex-
ression of Nox2 and Nox4 mRNA did not differ signifi-
antly between normal valves and noncalcified regions of
tenotic valves. However, Nox2 and Nox4 mRNA levels in
Valves
and calcified regions of stenotic aortic valves (n  16 normal valves, n  15
valves, n  11 stenotic valves; *p  0.05 vs. normal valves; #p  0.05 vs.
s in Figure 1.
Figure 4 Catalase Expression in Normal Valves and Noncalci-
fied and Calcified Regions of Stenotic Aortic Valves
n  10 normal valves, n  11 stenotic valves; *p  0.05 versus normal
valves; #p  0.05 versus noncalcified stenotic tissue. Abbreviations as in Fig-
ures 1 and 3.ortic
alcified
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Oxidative Stress in Aortic Valve Stenosis September 2, 2008:843–50alcified regions of stenotic valves were significantly de-
reased compared with normal valve tissue (Fig. 5A).
Addition of exogenous NADPH produced similar in-
reases in superoxide in tissue homogenates of calcified and
oncalcified valves (Fig. 5B). Thus, NADPH oxidase ac-
ivity was similar in calcified and noncalcified regions of the
alve. Addition of the flavin-containing enzyme inhibitor
iphenyliodonium decreased superoxide levels in calcified
alve homogenates, but the more specific NADPH oxidase
nhibitor apocynin did not reduce superoxide levels (Fig. 5D).
Inhibition of the flavin-containing nitric oxide synthases
NOS) with nitro-L-arginine methyl ester (L-NAME) signif-
cantly reduced superoxide levels in both noncalcified and
alcified regions of stenotic valves (Figs. 5C and 5D), which
uggests a possible role for uncoupling of NOS. Neither
ndomethacin nor allopurinol reduced superoxide levels in
oncalcified or calcified aortic valve tissue (data not shown).
haracterization of tissue with increased oxidative stress.
e did not observe consistent immunostaining for macro-
hages in regions with elevated oxidative stress (Fig. 6).
owever, tissue in calcified and peri-calcified regions of
tenotic valves consistently expressed high levels of -smooth
uscle actin (Fig. 6), which is consistent with an activated
Figure 5 Pro-Oxidative Enzymes in Normal and Stenotic Aortic
(A) Expression of subunits of nicotinamide adenine dinucleotide phosphate (NADP
noncalcified and 15 calcifed regions). (B) The NADPH oxidase activity in normal (n
fied regions). Effects of inhibitors of enzymatic sources of superoxide in noncalcifie
hanced chemiluminescence (n  5 to 11/group). APO  apocynin; DPI  diphenyyofibroblast phenotype. pxpression of genes related to calcification. Tissue in
alcified regions of stenotic valves had intense immunoflu-
rescence for the pro-osteoblast transcription factor Msx2
Figs. 7C and 7D), and modest immunofluorescence of
sx1 (Figs. 7A and 7B). Interestingly, immunofluorescence
or the osteogenic transcription factor CBFA1/Runx2 was
ignificantly increased in noncalcified regions of stenotic
alves compared with normal tissue. In contrast, staining for
BFA1 was not prominent in calcified regions of stenotic
alves (Figs. 7E and 7F), which is consistent with mRNA
evels (Fig. 7H). Expression of osteopontin mRNA in valve
issue was similar between normal valves and noncalcified
egions of stenotic valves but was significantly increased in
he calcified regions of stenotic valves (Fig. 7G).
iscussion
he main findings of this study are: 1) levels of superoxide
nd H2O2 are markedly increased in calcified regions of
tenotic aortic valves from humans; 2) expression and
ctivity of antioxidant enzymes are reduced in calcified
egions of stenotic aortic valves; and 3) superoxide produc-
ion in calcified aortic valves seems to be related at least in
s
dase in normal (n  16) and stenotic aortic valves (n  15 valves, with 15
ase and tip regions) and stenotic aortic valves (n  14 calcified and noncalci-
and calcified (D) regions of stenotic aortic valves measured with lucigenin-en-
m; RLU  relative light units; other abbreviations as in Figures 1 and 3.Valve
H) oxi
 8 b
d (C)
lidoniuart to uncoupling of NOS but not to increases in NADPH
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September 2, 2008:843–50 Oxidative Stress in Aortic Valve Stenosisxidase activity. Thus, oxidative stress is increased in ste-
otic aortic valves, but mechanisms that account for oxida-
ive stress differ greatly from those observed in atheroscle-
otic arteries (Fig. 8).
eactive oxygen species are increased in calcified regions
f stenotic valves. We found increases in superoxide and
2O2 levels near calcified regions of stenotic aortic valves.
his finding is similar to changes in atherosclerotic plaques,
here superoxide seems to play an important role in the
ocal inflammatory response (18,19), migration and prolif-
ration of vascular smooth muscle (20,21), and endothelial
ysfunction (22–24). Several of these effects might be
ediated by increased oxidative stress, reducing the bio-
vailability of nitric oxide and the promotion of uncoupled
OS activity (25,26).
The close association between calcification and oxidative
tress in the present investigation broaches the question: do
ncreases in oxidative stress cause valvular calcification or are
ncreases in oxidative stress an epiphenomenon associated
ith aortic valve stenosis? This study does not address this
uestion, but many genes related to soft tissue calcification
15), inflammation (19), and matrix remodeling (27) are
egulated by oxidative stress. Increased oxidative stress
ight play a role in the early stages of valve disease by
riving myofibroblast activation (28). These “activated” cells
Figure 6 Macrophage and Activated
Myofibroblast Markers in a Stenotic Human Valve
Antibodies against CD68 and -SMA were used to detect macrophages and
activated myofibroblasts, respectively, in noncalcified and calcified regions.
Representative images from n  5. Inset images are negative control images
from adjacent sections.re capable of subsequent transdifferentiation to cells withn osteoblast phenotype. Evidence for a role of oxidative
tress in transdifferentiation to an osteoblast-like cell differ-
ntiation has been provided in vitro, where generation of
ither superoxide or H2O2 increases the formation of
Figure 7 Immunofluorescent Staining in Noncalcified
and Calcified Regions of Stenotic Aortic Valves
Immunofluorescent staining for Msx1 (A and B), Msx2 (C and D), and CBFA1
(E and F) in noncalcified and calcified regions of stenotic aortic valves (inset
images are negative control images from adjacent sections; representative
images from n  5/stain). Panels G and H show messenger ribonucleic acid
(mRNA) levels of osteopontin and CBFA1/Runx2 mRNA in normal valves and in
noncalcified and calcified regions of stenotic aortic valves (*p  0.05 vs. nor-
mal tissue, #p  0.05 vs. noncalcified stenotic tissue, n  8/group). Abbrevia-
tions as in Figure 1.
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Oxidative Stress in Aortic Valve Stenosis September 2, 2008:843–50alcified nodules in vascular muscle (15). Thus, it is reason-
ble to speculate that oxidative stress might be upstream in
everal signaling cascades related to changes in the aortic
alve. Whether increases in oxidative stress play a key role in
nitiation and progression of aortic valve disease in vivo has
ot yet been demonstrated.
ecreased antioxidant enzyme function contributes to
ncreases in oxidative stress. We found that expression
nd activity of CuZnSOD, MnSOD, and ecSOD were
ecreased in calcified regions of stenotic valves and thus
ight contribute to increases in superoxide in these regions.
hese changes are directionally opposite from those ob-
erved in atherosclerotic plaques, where expression of
uZnSOD and MnSOD is unchanged and ecSOD expres-
ion is increased (16). We speculate that this finding could
e explained by: 1) downregulation or repression of SOD
xpression (29); 2) impairment of mechanisms that upregu-
ate SOD expression (e.g., peroxisome proliferator-activated
eceptor gamma [30,31]); or 3) paradoxical reductions in
ro-inflammatory stimuli that might occur in end-stage
ortic valve stenosis (32).
Hydrogen peroxide was increased in stenotic aortic valves
espite decreases in SOD activity. In contrast to atheroscle-
otic plaques, where increased dismutation of superoxide by
levated SOD levels contributes to increases in H2O2 (33),
ncreases in peri-calcific H2O2 in the valve cannot be
xplained by increases in SOD activity. Instead, reductions
n antioxidant enzymes related to H2O2 catabolism might
ontribute to increases in levels of H2O2. Support for this
ypothesis is provided by our observation that expression of
atalase was reduced in the calcified regions of the valve.
hus, reduced expression of proteins that catabolize perox-
Figure 8 Different Mechanisms Generating Oxidative Stress in
Vascular Lesions and Calcifed Stenotic Aortic Valves
↔  no change; /  increases or decreases have been reported; NADPH
 nicotinamide adenine dinucleotide phosphate; NOS  nitric oxide synthase.de in calcified valve tissue resembles atherosclerotic lesions, ahere expression of catalase and glutathione peroxidase-1
re also reduced (34,35).
Determining the role of H2O2 in the pathophysiology of
ardiovascular diseases has proven to be difficult. One reason
s that altering the expression of enzymes related to the
atabolism of H2O2 is likely to alter the expression of other
enes (e.g., through epidermal growth factor receptor trans-
ctivation). Overexpression of CuZnSOD paradoxically ac-
elerates the development of atherosclerosis in apolipopro-
ein E/ mice and can be “rescued” by overexpression of
atalase (33). This finding suggests that H2O2 might play
n important role in the development of atherosclerosis.
ources of superoxide in calcified regions of stenotic
alves. A surprising finding in the present study was that
ADPH oxidase activity was not increased in the calcified
egions of stenotic valves, and expression of the catalytic
ubunits of the oxidase was unchanged or decreased. These
ndings contrast with observations in atherosclerotic
laques, where upregulation of the catalytic subunits of
ADPH oxidase plays a key role in increasing oxidative
tress (16,36).
We used several inhibitors to examine potential sources of
uperoxide production in the calcified regions of stenotic
alves. Diphenyliodonium (a nonspecific inhibitor of flavin-
ontaining enzymes, including NADPH oxidase) reduced
uperoxide levels. We found, however, that specific inhibi-
ion of the NOS (which are also flavin-containing enzymes)
ith L-NAME produced the most consistent reductions in
uperoxide levels. This finding is surprising, because nitric
xide generated by NOS quenches superoxide, and
-NAME would therefore be expected to increase super-
xide levels.
The finding that superoxide is reduced by L-NAME
ould be explained by “uncoupling” of enzymatic activity of
ndothelial, inducible, or neuronal NOS, which might occur
uring a deficiency in 1 or more cofactors required for the
eneration of nitric oxide (25,26). Depletion of the NOS
ofactor tetrahydrobiopterin (BH4) can result in generation
f superoxide radicals by NOS (37). Local biopterin levels
eem to be a critical determinant of NOS function (38), are
odulated by levels of peroxynitrite (which oxidize BH4 to
H3), and can be increased by antioxidants (37).
xpression of genes related to calcification. We found
hat, similar to previous studies (14), expression of tissue
steopontin was markedly increased in the calcified region
f stenotic aortic valves. Although increased plasma os-
eopontin levels are thought to confer protection against soft
issue calcification, elevated tissue levels of osteopontin might
ctually augment soft tissue calcification by increasing local
nflammation and activity of matrix metalloproteinases (39).
We also found increases in expression of CBFA1/Runx2
n stenotic aortic valves, although these increases were most
ronounced in noncalcified regions of the valve. This
nding might reflect early stages of myofibroblast transdif-
erentiation to a more osteoblast-like phenotype, because
lterations in Smad tone and increases in CBFA1/Runx2
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September 2, 2008:843–50 Oxidative Stress in Aortic Valve Stenosislay a key role in transdifferentiation in myoblastic (40) and
ascular smooth muscle cells (41). Interestingly, we ob-
erved marked increases in Msx2 immunofluorescence in
alcified regions of stenotic valve, which suggest that Msx2
ight be promoting further differentiation of activated
yofibroblasts to an osteoblast-like phenotype in the calci-
ed regions of the valve, perhaps through canonical Wnt
ignaling pathways (42).
tudy limitations. An inherent limitation of our study of
iseased tissue from humans with end-stage disease is that
e are unable to examine experimentally whether increases
n oxidative stress drive valvular calcification or whether
xidative stress is an epiphenomenon associated with the
isease. Nevertheless, these findings provide strong evidence
or an association but not necessarily a causal relationship
etween oxidative stress and aortic stenosis and lay the
roundwork for mechanistic studies.
We did not collect clinical information from the
atients whose valves were used in these studies. Conse-
uently, we are not able to examine variability within a
roup by drug treatment or comorbid conditions. Nu-
erous drugs reduce oxidative stress via increases in
ntioxidant enzyme expression or by reducing NADPH
xidase activity. Consequently, oxidative stress might be
onsiderably higher in animal models of aortic valve
tenosis or in stenotic valves from patients who are not
eceiving optimal pharmacotherapy. In addition, there
re compelling data linking acceleration of lesion forma-
ion and calcification by diabetes to activation of
ADPH oxidase (39,43). Thus, in some patients (per-
aps especially diabetic patients), we cannot exclude the
ossibility that increases in NADPH oxidase activity
ontribute to oxidative stress in the aortic valve.
An unusual aspect of our tissue acquisition process is that
he time from tissue explantation to placing the tissue in
ce-cold buffer is 15 min. Additionally, our normal valve
roup was not composed of tissues gathered at autopsy but
nstead were “transplant quality” tissues acquired from organ
rocurement organizations (see Online Appendix). Thus,
hanges in oxidative stress or enzymatic activity probably
annot be attributed to differences in time to post-explant
issue preservation.
linical implications. Treatments that effectively slow
he progression of aortic valve stenosis have proven
lusive (32,44,45). Retrospective studies suggest that
statins” (46) and angiotensin-converting enyme inhibi-
ors (47) might slow the progression of aortic valve
tenosis, although prospective studies have yielded con-
icting results (32,48). Both statins and angiotensin-
onverting enyme inhibitors also reduce oxidative stress
49), and it is possible that interventions specifically
argeting oxidative stress during earlier stages of the
isease (e.g., when patients have aortic sclerosis) might
low the progression of aortic valve stenosis.onclusions
xidative stress is increased in calcified regions of stenotic
ortic valves. In striking contrast to atherosclerotic lesions,
ncreased oxidative stress seems to be due in part to
eductions in antioxidant enzyme expression and activity.
urthermore, NOS uncoupling might play an important
ole in the generation of superoxide in calcified aortic valves.
dditional studies are needed to experimentally test
hether oxidative stress is a viable therapeutic target to slow
he progression of aortic valve stenosis.
dded note in proofs. After submission of this paper,
nother article was published by Liberman et al. (50) that
lso indicated that oxidative stress occurs in stenotic aortic
alves.
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